Making Sense of the Current SPAC Market: Are SPACs still a viable pathway to going public?
Event Details
All registrants to this free webinar will receive a copy of the recording, whether or not you are able to join live for Q&A Within the past year
Event Details
| All registrants to this free webinar will receive a copy of the recording, whether or not you are able to join live for Q&A |
| Within the past year the role in biotech of special purpose acquisition companies (SPAC) has moved from a rarefied interest to a core option for reaching public markets, now attracting high levels of investor and regulator attention. Learn through live Q&A with a panel of SPAC deal experts how this popular, volatile tool for raising capital works in practice and will evolve next.
Register here! Sponsored by: Chardan Moderator: Barbara Ryan, Founder, Barbara Ryan Advisors; Editorial Advisory Board, Pharmaceutical Executive; Senior Advisor, EY Panelists: Jonas Grossman, President and Managing Partner, Chardan Rakhi Kumar, Chief Accounting Officer, Roivant Sciences Ryan Maierson, Partner, Latham & Watkins LLP Carlo Passeri, Director, Biotechnology Capital Markets, Biotechnology Innovation Organization (BIO) |
Time
(Wednesday) 11:00 am - 12:00 pm(GMT-11:00)
Location
Online Webinar